HK Stock Market Move | XUANZHUBIO-B (02575) surged over 8% in early trading. The company will announce its mid-term performance today. Institutions indicate that Annelore Sodium has enormous commercial potential.

XUANZHUBIO-B (02575) rose over 8% in early trading, and as of publication, it had increased by 5.9% to HKD 11.13, with a trading volume of HKD 2.7311 million. In news, Xuan Zhu Biological announced that a board meeting will be held on August 26, 2026 (Wednesday) to consider and approve the groups interim results for the six months ending June 30, 2026, and to consider the proposal for an interim dividend (if any). Notably, Xuan Zhu Biological recently announced that the NDA application for the new generation PPI inhibitor, Anaprazole Sodium Enteric-Coated Tablets, for the treatment of adult gastroesophageal reflux disease (GERD) has been accepted by the NMPA, based on the results of a domestic phase III trial that was randomized, double-blind, and controlled against Rabeprazole. GERD is the second indication for an NDA following duodenal ulcers. Zhongyou Securities released a research report stating that the companys Anaprazole Sodium has clinical advantages over previous-generation PPI inhibitors and offers price and safety advantages over PCABs. It is currently covering nearly 3,000 medical terminals, indicating significant commercial potential in the future.